Html code here! Replace this with any non empty raw html code and that's it.

Spain introduces new treatment for genetic ALS

Date:

Share this article:

Del denne artikel:

A Spanish hospital has begun administering a newly approved therapy for patients with a rare genetic form of ALS.

A life-changing diagnosis often brings uncertainty and limited options. For people living with ALS, medical progress has historically been slow, and families quickly learn to measure change in small steps.

Now, a hospital in Barcelona has begun using a newly approved drug aimed at a specific genetic form of the disease.

A targeted rollout

Hospital Germans Trias has started treating a 44-year-old patient with Tofersen, a therapy designed for ALS linked to mutations in the SOD1 gene.

This inherited variant represents a small share of total ALS cases but is among the more common genetic forms.

Also read: Declining birth rates may affect the risk of ovarian cancer

The European Medicines Agency authorized the treatment in 2024 under special conditions. Spain’s Ministry of Health later approved and funded its use within the public healthcare system.

What studies show

International clinical trials indicate the drug can slow functional decline, help preserve respiratory capacity and improve muscle strength in patients with SOD1-related ALS.

Data reported from participating centers, including Bellvitge Hospital, found that about one in four patients showed early improvements on clinical function scales.

The therapy is delivered through lumbar punctures, with three initial doses given at two-week intervals, followed by monthly administrations.

Also read: Why your urine may smell like popcorn - and when to be concerned

Its delivery requires coordination across neurology, anesthesiology, pharmacy and outpatient care teams.

The wider context

ALS, or amyotrophic lateral sclerosis, is a progressive neurodegenerative disease that damages motor neurons controlling voluntary movement.

As it advances, patients typically lose mobility, speech, swallowing ability and eventually respiratory function.

Average life expectancy after diagnosis is commonly three to five years, and there is no cure.

Also read: Trying to improve your gut? Start with fiber variety

For patients with the SOD1 mutation, the introduction of Tofersen is a notable development in a field where new treatment options have been rare.

Sources: Infobae

Also read: Why some experts recommend washing feet with vinegar and salt

Other articles

Nutrition researcher: Why you should eat more berries

According to a nutrition researcher, berries offer several health benefits.

New research reveals what anesthesia does to your brain

Many people think of anesthesia as nothing more than a deep sleep, but new research suggests the brain...

Migraine with aura linked to 73 percent higher risk of stroke

Some types of migraine may be associated with a higher risk of stroke, according to a new study.

Craving candy? Try dried jackfruit instead

Many people reach for candy when they crave something sweet, but dried jackfruit could be a good alternative.

Nutrition researcher: Why you should eat more berries

According to a nutrition researcher, berries offer several health benefits.

New research reveals what anesthesia does to your brain

Many people think of anesthesia as nothing more than a deep sleep, but new research suggests the brain...

Migraine with aura linked to 73 percent higher risk of stroke

Some types of migraine may be associated with a higher risk of stroke, according to a new study.